SC 105
Latest Information Update: 04 Jul 2000
Price :
$50 *
At a glance
- Originator Scotia Holdings [CEASED]
- Class Antirheumatics; Nonsteroidal anti-inflammatories
- Mechanism of Action Prostaglandin synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Musculoskeletal disorders; Osteoarthritis
Most Recent Events
- 04 Jul 2000 Discontinued-Preclinical for Musculoskeletal disorders in United Kingdom (Unknown route)
- 04 Jul 2000 Discontinued-Preclinical for Osteoarthritis in United Kingdom (Unknown route)
- 09 Mar 1999 No-Development-Reported for Musculoskeletal disorders in United Kingdom (Unknown route)